Q4 and full year 2022 in line with expectations at €2.7 million and €7.5 million, respectively U.S. level of sales stable in 2022 at...
Search Results
Mauna Kea Technologies Announces the Publication of Results of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy for Lung Cancer
Results were published in Respirology and provide further evidence supporting Cellvizio as a key complementary technology to robotic-assisted...
Mauna Kea Technologies reports its Financial Results for the First Half of 2022
Improvement in gross margin driven by a more favorable sales mix and reduction in operating loss Solid business activity following strategic...
Mauna Kea Technologies and Tasly Pharmaceutical Announce the Incorporation of Joint Venture in China
Tasly Mauna Kea Medical Engineering Technology Co. Ltd will expand reach of Cellvizio in China and launch a dedicated platform for neurosurgical...
Mauna Kea Technologies Announces Success of Clinical Trial on Prediction of Remission in Patients with Inflammatory Bowel Disease (IBD) and its Publication in Gastroenterology
Dynamic monitoring of the intestinal barrier with Confocal Laser Endomicroscopy demonstrated to be far superior to endoscopic and histologic...
Mauna Kea Technologies Announces 2022 Nine Month Sales Results
Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23% Mauna Kea Technologies today announced...
Mauna Kea Technologies Announces the Appointment of Sacha Loiseau as Chief Executive Officer
Mauna Kea Technologies today announces the appointment of Sacha Loiseau, Founder and current Chairman of the Board of Mauna Kea Technologies, to...
Mauna Kea Technologies Postpones Release of its 2022 Half-Year Financial Results
Mauna Kea Technologies postpones release of its 2022 Half-Year Results, which was originally planned for September 22, 2022, to not later than...
On Target Laboratories and Mauna Kea Technologies Further Explore Targeted Detection and Real-Time Diagnosis of Lung Cancer with a Molecular Imaging Agent
Results of the 20-patient study published in the European Journal of Nuclear Medicine and Molecular Imaging demonstrated the potential for high...
Mauna Kea Technologies Announces Q2 and 1H 2022 Revenues
Stable YTD Revenue while Strategic Realignment Implemented 35% 1H U.S. Sales Growth offset by Declines in Asia Recently announced Tasly...
Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements
Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire...